scholarly journals Bifunctional Expression Vector Plasmid DNA-bi-shRNA EWS/FLI1 Type 1 Lipoplex

2020 ◽  
Author(s):  
Keyword(s):  
Plasmid Dna ◽  
Expression Vector ◽  
Vector Plasmid

scholarly journals Induction of Potent Human Immunodeficiency Virus Type 1-Specific T-Cell-Restricted Immunity by Genetically Modified Dendritic Cells

2001 ◽  
Vol 75 (16) ◽  
pp. 7621-7628 ◽  
Author(s):  
Julianna Lisziewicz ◽  
Dmitry I. Gabrilovich ◽  
Georg Varga ◽  
Jianqing Xu ◽  
Philip D. Greenberg ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Dendritic Cells ◽  
T Cell ◽  
Human Immunodeficiency Virus Type ◽  
Plasmid Dna ◽  
Genetically Modified ◽  
Ctl Response ◽  
Immunodeficiency Virus ◽  
Hiv 1

ABSTRACT A novel technology combining replication- and integration-defective human immunodeficiency virus type 1 (HIV-1) vectors with genetically modified dendritic cells was developed in order to induce T-cell immunity. We introduced the vector into dendritic cells as a plasmid DNA using polyethylenimine as the gene delivery system, thereby circumventing the problem of obtaining viral vector expression in the absence of integration. Genetically modified dendritic cells (GMDC) presented viral epitopes efficiently, secreted interleukin 12, and primed both CD4+ and CD8+ HIV-specific T cells capable of producing gamma interferon and exerting potent HIV-1-specific cytotoxicity in vitro. In nonhuman primates, subcutaneously injected GMDC migrated into the draining lymph node at an unprecedentedly high rate and expressed the plasmid DNA. The animals presented a vigorous HIV-specific effector cytotoxic-T-lymphocyte (CTL) response as early as 3 weeks after a single immunization, which later developed into a memory CTL response. Interestingly, antibodies did not accompany these CTL responses, indicating that GMDC can induce a pure Th1 type of immune response. Successful induction of a broad and long-lasting HIV-specific cellular immunity is expected to control virus replication in infected individuals.

scholarly journals Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform

2013 ◽  
Vol 149 (3) ◽  
pp. 297-306 ◽  
Author(s):  
Peter Gottlieb ◽  
Paul J Utz ◽  
William Robinson ◽  
Lawrence Steinman
Keyword(s):  
Type 1 Diabetes ◽  
Plasmid Dna

Recombinant Glycoprotein B of Equine herpesvirus Type 1 Elicits Protective Immune Response against Challenge in BALB/c Mouse Model

2021 ◽  
Author(s):  
Alok Joshi ◽  
R.P. Gupta ◽  
Selvaraj Pavulraj ◽  
Bidhan Chandra Bera ◽  
Taruna Anand ◽  
...  
Keyword(s):  
Immune Response ◽  
Plasmid Dna ◽  
Protective Immune Response ◽  
Glycoprotein B ◽  
Equine Herpesvirus ◽  
Recombinant Glycoprotein ◽  
Herpesvirus Type ◽  
Equine Herpesvirus Type ◽  
Equine Herpesvirus Type 1

Background: Equine herpesvirus type 1 (EHV-1) is the most important viral pathogen of equines, causing respiratory illness, abortion, neonatal foal mortality and neurologic disorders. Large numbers of commercial EHV-1 vaccines are available to protect equines from the disease, but they provide only partial protection. Despite immunization with inactivated and modified live virus vaccine, mares show abortions. Present study was aimed to investigate the immunogenicity and protective efficacy of EHV-1 recombinant glycoprotein B (rgB) and gB expressing plasmid DNA against EHV-1 infection in BALB/c mice model.Methods: About 3-4 weeks old 225 female BALB/c mice were selected for the comparative study of immunization followed by challenged with EHV-1/India/Tohana/96-2 strain virus in 5 different groups of 45 animals each.Result: Following immunization, rgB vaccinated mice showed optimal stimulation of EHV-1 gB specific cell mediated and humoral mediated immunity (HMI and CMI). The gB expressing plasmid DNA vaccinated mice developed only CMI while inactivated whole virus vaccinated mice had only HMI. Upon EHV-1 challenge, all infected mice displayed variable levels of clinical signs with changes in body weight, however, vaccinated mice showed very rapid recovery with optimal protection. Positive control group mice showed severe pulmonary lesions along with persistence virus infection till 5 days post challenge (dpc) whereas vaccinated mice had less pulmonary lesion only up to 3dpc. Minimal lung lesions and early virus clearance was observed in the rgB immunized mice in comparison to the gB plasmid DNA and inactivated EHV-1 vaccine immunized mice. It has been concluded that immunization with rgB elicits optimum protective immune response against EHV-1 infection in mice model. The rgB could be a potential vaccine candidate against EHV-1 infection in equine in the future.

scholarly journals BK virus-plasmid expression vector that persists episomally in human cells and shuttles into Escherichia coli.

1984 ◽  
Vol 4 (8) ◽  
pp. 1551-1560 ◽  
Author(s):  
G Milanesi ◽  
G Barbanti-Brodano ◽  
M Negrini ◽  
D Lee ◽  
A Corallini ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Expression Vector ◽  
Selective Pressure ◽  
T Antigen ◽  
Bk Virus ◽  
Human Cells ◽  
Transformed Cells ◽  
Low Molecular Weight ◽  
Simplex Virus

We describe a novel expression vector, pBK TK-1, that persists episomally in human cells that can be shuttled into bacteria. This vector includes sequences from BK virus (BKV), the thymidine kinase (TK) gene of herpes simplex virus type 1, and plasmid pML-1. TK+-transformed HeLa and 143 B cells contained predominantly full-length episomes. There were typically 20 to 40 (HeLa) and 75 to 120 143 B vector copies per cell, although some 143 B transformants contained hundreds. Low-molecular-weight DNA from TK+-transformed cells introduced into Escherichia coli were recovered as plasmids that were indistinguishable from the input vector. Removal of selective pressure had no apparent effect upon the episomal status of pBK TK-1 molecules in TK+-transformed cells. BKV T antigen may play a role in episomal replication of pBK TK-1 since this viral protein was expressed in TK+ transformants and since a plasmid that contained only the BKV origin of replication was highly amplified in BKV-transformed human cells that synthesize BKV T antigen.

Sign in / Sign up

Export Citation Format

Share Document